Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...

Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for ...

A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar ...

Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its ...

Regeneron (REGN) stock was downgraded by Leerink after a court ruling that favored Amgen's (AMGN) plans to introduce a biosimilar for REGN's Eylea. Read more here.

Regeneron Pharmaceuticals is a leading biotech firm with a strong portfolio. Click here to know what justifies a Buy rating ...

Regeneron sued Amgen in January, alleging that it was developing a biosimilar that violated key patent protections for Eylea.

Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...

In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...

Jefferies analyst Akash Tewari maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...